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OF DEEP BRAIN STIMULATION OF THE SUBTHALAMIC NUCLEUS IN A
PARKINSONIAN RAT MODEL
Carter Mulder
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF MASTER OF ARTS IN CLINICAL
PSYCHOLOGY

MINNESOTA STATE UNIVERSITY, MANKATO
MANKATO, MINNESOTA

ABSTRACT
Parkinson’s disease (PD) is estimated to impact nearly 10 million people globally and is
estimated to increase in the future. PD is a progressive neurodegenerative disease that worsens
through continuous cell death of dopaminergic neurons. This cell death can create motor
symptoms such as bradykinesia, tremor, and muscular rigidity. Subthalamic nucleus deep brain
stimulation, STN DBS, is a surgical intervention which places stimulating electrodes in the STN
greatly improving motor symptoms. However, STN DBS has been reported to possibly influence
non-motor symptoms such as anxiety both acutely and long-term, which decreases the quality of
life for those with PD. We hypothesize that acute and chronic STN DBS will produce more
anxiety-like behavior in a rat model of PD compared to PD rats that are not stimulated. Nineteen
rats underwent stereotactic surgery and were bilaterally lesioned in the dorsal striatum with 6Hydroxydopamine to create PD phenotype and neuropathology. Each rat had a stimulating
electrode unilaterally implanted into the STN. All rats were recorded for 10 minutes in the open
field behavior paradigm to examine anxiety-like behavior such as rearing, grooming, and time
spent in by the walls and in the center, along with measures of locomotion such as total distance
traveled and velocity. Statistical analysis of each measure within the initial five minutes and total
ten minutes of the open field arena did not reveal any significant differences between groups.
Limitations including differences between clinical and animal studies, absence of histological
confirmation of lesion and electrode placement, small sample size, lack of appropriate controls,
and additional behavior paradigm to measure anxiety-like behavior likely contributed to the
current lack of significant results. We concluded that STN DBS does not create more anxiety-
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like behavior in acutely or chronically stimulated rat models of PD compared to PD rats that
were not stimulated.

1
Investigating Anxiety-Like Behavior as a Non-Motor Side Effect of Deep Brain Stimulation
of the Subthalamic Nucleus in a Parkinsonian Rat Model
The Socio-Economic Impact of Parkinson’s Disease
In 2016 the prevalence of Parkinson’s disease (PD) was of approximately 700 thousand
in the United States (US) and 6.1 million globally, with an increase in incidence of 22% from
1990 to 2016 (Dorsey et al., 2018, p. 939). Presently, there are 930 thousand individuals living
with PD in the US and 9.4 million in the world (Maserejian & Vinikoor-Imler, 2020).
Additionally, PD shows a consistent increase in premature mortality and years of life lived with
disability (Feigin et al., 2017, p. 885).
With the sharp increase in prevalence and disability, the economic impact of PD has
grown. Kowal and colleagues (2013) estimated that PD cost individuals $14.4 million in direct
medical expenses and over $6.3 million in other indirect costs due to factors such as decreased
employment to adult day care expenses (p. 314-316). A more recent study conducted by Yang
and colleagues in 2020, found a significant rise from the previous 2013 analysis. They reported a
total economic burden of $51.9 billion, almost a 151% increase in economic burden, with an
estimated future economic burden of $79.1 billion (p. 1, 5). These results illustrate the
concerning and increasing trend of PD prevalence and economic burden in our society.
The Pathophysiology of Parkinson’s Disease
PD is a progressive neurodegenerative disease that worsens through continuous cell death
(Dauer & Przedborski, 2003; Hawley et al., 2014). PD is characterized by the loss of
dopaminergic neurons in the substantia nigra pars compacta (SNc), and the presence of abnormal
alpha-synuclein (α-syn) protein that accumulate to form intracellular inclusions called Lewy
bodies (Hawley et al., 2014; Jakobs et al., 2019).
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A complex interplay between genes and the environment shapes the development of PD.
Genetic mutations and multiplications to specific genes can cause PD, such as SNCA, which
codes α-syn, and PRKN and LRRK2 that code enzymes involved in mitochondrial dysfunction
and apoptosis, cell death of dopaminergic neurons (Lill & Klein, 2017). Other environmental
factors have been found to cause PD, such as the groundbreaking discovery of 1-methyl 4-phenyl
1,2,3,6-tetrahydropiridinium (MPTP), a neurotoxin that causes dopaminergic cell death in the
SNc (Dauer & Przedborski, 2003; Nonnekes et al., 2018). Studies also show that exposure to
heavy metals, pesticides and herbicides, and other chemicals may cause similar damage and
degenerations in the basal ganglia and dopaminergic neurons (Ball et al., 2019; Dauer &
Przedborski, 2003).
Clinical presentations of PD principally manifest as motor deficits that include
bradykinesia, or slowness of movements, resting tremor, and muscle rigidity (Pahwa & Lyons,
2012). In general, PD falls in the spectrum of hypokinetic neurological disorders because
voluntary movements have a reduced velocity and amplitude, actions are slow in speed and
direction and smaller in size (Bologna et al., 2016). PD is also marked by postural instability, or
difficulty maintaining balance when executing movements, standing still, preparing to move, or
attempting to correct oneself after losing equilibrium (Palakurthi & Burugupally, 2019). A result
of both bradykinesia and postural instability are difficulties with gait, one’s pattern of movement.
Abnormal gait patterns seen in PD include festinating gait, small quick successive steps like
running; freezing of gait, or the stopping of forward motion regardless of the desire to move,
which can be seen as walking in place; and shuffling gait, small steps like festinating gait but
slower (Chen et al., 2013; Mirelman et al., 2019; Nonnekes et al., 2019). Muscle rigidity is an
involuntary, velocity-independent resistance to movement at the joint that can be expressed as
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quick, jerky movements or a singular, snapping motion decreasing the smoothness of a
movement (Armstrong & Okun, 2020; di Biase et al., 2018). Finally, the resting tremor, or often
called “pill-tremor”, is a rhythmic motion where the individual rubs their thumb and pointerfinger together (Kaindlstorfer et al., 2013). These motor deficits are the core characteristics of
PD and help contribute to its diagnosis and significantly reduce quality of life for the individual.
The Cortico-Basal Ganglia Motor Loop and its Importance in Parkinson’s Disease
The basal ganglia (BG) comprise a group of interconnected subcortical nuclei that
regulate functions including voluntary movement, cognitive planning, motivation, and limbic
processing (Sonne et al., 2021, par. 1). Specifically, action-selection, the main functional
component that governs voluntary movement, is under control of the cortico-BG motor loop
(Frank and Claus, 2006; Frank, 2011; Isoda and Hikosaka, 2011; Mink, 1996; Mogenson et al.,
1980). Figure 1A below illustrates how the cortico-BG motor loop regulates normal motor
function. In this circuitry, information from nearly all cortical and limbic subcortical areas flow
into the BG input stations, including the dorsal striatum (DS) and the subthalamic nucleus
(STN). The DS is composed of inhibitory GABAergic projection neurons named medium spiny
neurons (MSNs) that form projections to the main output stations of the BG: the substantia nigra
pars reticulata (SNr) and the globus pallidus internus (GPi). MSNs also form distinct indirect
projections to the BG output nuclei via the globus pallidus externus (GPe). The SNr/GPi project
mostly to motor areas of the thalamus, which in turn, project to motor areas of the neocortex.
Activation of MSNs of the direct pathway are responsible for inhibiting inhibition, removing
inhibition of neurons for excitation to occur, resulting in a ‘go’ signal to initiate movement.
Activation of MSNs of the indirect pathway are responsible for inhibition disinhibition,
reinstating inhibition of these neurons, which serves as ‘stop’ signal to inhibit movement.
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Additionally, the inhibitory control of the BG over the thalamocortical neurons can be increased
by the hyperdirect pathway formed by cortical projections that bypass the DS by sending
“hyperdirect” excitatory projections to the STN that stimulate the SNr/GPi input onto the
thalamus. The hyperdirect pathway of cortical projections to the STN, which stimulate the SNr
and GPi provide overall inhibition of unnecessary movement (Da Cunha et al., 2015). Finally,
the DS MSNs are differentially regulated by dopaminergic (DA) efferents originating from the
SNc via activation of stimulatory D1 receptors (D1R), preferentially expressed in MSNs of the
direct pathway, and activation of inhibitory D2 receptors (D2R), preferentially expressed in
MSNs of the indirect pathway. Thus, activation of both D1R and D2R in the direct pathway and
indirect pathways culminates in the facilitation of movement by increasing the ‘go’ signal and
decreasing the ‘stop’ signal, respectively (Da Cunha et al., 2015).
Figure 1B below shows the changes that occur to the cortico-BG motor loop in PD. The
reduction in DA transmission onto DS MSNs prevents activation of the direct pathway and
prevents inhibition of the indirect pathway. Therefore, the go signal cannot be activated, and the
stop signal is enhanced ultimately causing inhibition of motor nuclei in the thalamus. The result
is the inhibition of movement initiation (akinesia) and execution (bradykinesia), and increased
inhibition of ongoing movements (muscular rigidity) (Okun, 2012).
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Figure 1
Proposed Functioning of the Cortico-BG Motor Loop in Healthy Individuals (A) vs. PD (B)

A)

B)
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Note. Image A) depicts normal functioning in the cortico-BG motor loop. Image B) depicts the
hypokinetic cortico-BG motor loop in PD.
What is Deep Brain Stimulation?
Therapeutic Process of Deep Brain Stimulation
Deep brain stimulation (DBS) is a well-established surgical intervention to treat the
motor symptoms of PD (Aviles-Olmos et al., 2014; Goetz et al., 2005; Obeso et al., 2001). DBS
entails surgically implanting a stimulating electrode into certain brain regions so that delivery of
continuous high frequency electrical stimulation modulates the neuronal activity of
interconnected circuitry. The stimulating electrode is subcutaneously connected to an
implantable pulse generator that provides power to generate and maintain electrical stimulation.
In PD, the electrode is placed into specific regions within the cortico-BG motor loop, namely the
STN and the GPi. It is suggested that STN and GPi DBS inhibit pathological patterns of neuronal
firing in the cortico-BG motor loop resulted from poor dopaminergic transmission; however, the
therapeutic process is not completely understood (Hamani et al., 2017; Jakobs et al., 2019).
Current suggests that STN DBS may overwrite tonic inhibition on the thalamus by stimulating
the STN and its efferents, removing the inhibition on the GPi and SNr, allowing the thalamus to
once again send “go” signals to the motor cortices, thus regulating the cortico-BG motor loop
(Da Cunha et al., 2015).
Side Effects of Deep Brain Stimulation
The benefits of STN DBS in reducing the motor symptoms in parkinsonian patients are well
documented (Aviles-Olmos et al., 2014; Obeso et al., 2001; Ramirez-Zamora & Ostrem, 2018;
Wong et al., 2020). STN DBS, but not GPi DBS, also has shown an ability to reduce
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antiparkinsonian drug treatment (Couto et al., 2014; Okun et al., 2009; Peng et al., 2018). For
this reason, STN DBS has become a preferred target in the treatment of the motor symptoms of
PD. There is, however, increasing evidence that STN DBS may be associated with higher
incidence of psychiatric side effects such as anxiety, depression, suicidal ideation, mania, and
others. These psychiatric side effects are often transient and treatable, but can be long-term,
especially when unaddressed (Chaudhuri & Schapira, 2009; Voon et al., 2006; Voon et al.,
2008).
Anxiety has been reported as a transient symptom during STN DBS parameter setting,
shortly following surgery, and during long-term stimulation (Abulseoud et al., 2016; Anderson et
al., 2005; Couto et al., 2014; Houeto et al., 2002; Temel et al., 2005; Voon et al., 2006).
Contrastingly, studies have also found no differences and even contradictory results reporting
positive changes in short- and long-term mood from baseline to post-operative assessments
(Couto et al., 2014; Kaiser et al., 2008; Lopiano et al., 2001; Rothlind et al., 2007; Wang et al.,
2016; York et al., 2008).
Moreover, Chang and colleagues (2012) used bilateral STN DBS while controlling for DA
medication found that anxiety-related PD was “influenced by the severity of the motor symptoms
and the level of life quality” as levels of anxiety mirrored increases and decreases in motor
function over time (p. 320, 322). The researchers also noted a correlation between changes in the
pulse-width (area of the stimulation) and duration (chronicity) of stimulation and anxiety. Higher
pulse-width and duration stimulation produced greater anxiety symptoms. On a similar note,
previous research by Kalteis and investigators (2006) reported that during individual assessment
of anxiety and other psychiatric non-motor side effects, these symptoms worsened regardless of
motor improvement. These results are of interest because of the anatomical structure of the STN.
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The STN has been found to be a key regulatory region of the cortico-BG motor loop.
However, the STN is also associated with cognitive and affective regulation because of its
overlapping topography with its cortical connections which determines three functional
subregions: a motor, an associative, and a limbic subregion (Temel et al., 2005). The STN also
has projections into other brain regions that regulate emotional processing such as the nucleus
accumbens, anterior cingulate, ventral pallidum, orbitofrontal cortex, ventral tegmental area, and
the amygdala (Péron et al., 2013; Temel et al., 2005). Research has shown that STN DBS can
influence an individual’s emotional state, more so when the ventral portion of the STN is
stimulated (Castrioto et al., 2014). Despite current evidence, no agreement or substantial
conclusion has been made in the divisions of the STN and their location, understanding of
neuronal connections to and from the STN, and why changes in anxiety occur. Hence, continued
investigation is needed as to what factors related to STN DBS may contribute or cause anxiety.
Animal Models
Subthalamic nucleus research with rodents has also implicated the STN in regulating
anxiogenic-like behavior, similar to our understanding of how STN DBS stimulation may elicit
anxiety in human patients as described above (Badstuebner et al., 2017; Reymann et al., 2013).
Animal models, particularly rodent models such as rats, have been increasingly incorporated into
neuroscientific research because of their ability to serve as accurate preclinical models of disease
and illness allowing results from rats to translate to humans. An apt explanation of understanding
animals in research was given by Dr. Michael Rand, DVM, in his chapter “Selection of
Biomedical Animal Models”. Dr. Rand writes, “...the term “animal model” is actually studying
human conditions. In other words, it is not the image of the preferred animal that is the focus of
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research but the analogy of the physiological behavior of this animal to our own (or another)
species” (2008, p. 10).
We utilize animal models of rats because of their many advantages. An important
advantage is that brain regions and circuitry are anatomically consistent between rats and
humans. Rats also provide an advantage because their brains are larger than other animal models
and rodents (i.e., mice, pigeons) allowing for easier stereotactic targeting when conducting
surgery for precise implantation of DBS or injection of neurotoxic chemicals to induce
Parkinson’s-like degeneration, and reducing the damage caused to surrounding tissue when
conducted (Bryda, 2013; Ellenbroek & Youn, 2016; Jonsson, 1983).
Behaviorally, rats can be trained with greater ease and exhibit behaviors analogous to
humans making them highly desirable when undergoing behavioral tests. Also, rats take less
time to train, to habituate to their surroundings, perform better over time, and are less affected by
external distractions than other models such as mice, a benefit when studying anxiety
(Ellenbroek & Youn, 2016). Moreover, routine handling of rats can further reduce their anxiety
prior to behavioral testing (Costa et al., 2012). Other important factors for the use of rats include
fewer expenses to acquire and maintain, and ease of training researchers to work with rodents
compared to non-human primates, which are considered the “gold standard” of PD DBS
translational research but are harder in each regard of the aforementioned information (Chia et
al., 2020; Pereira & Aziz, 2006, pp. 293, 295-296; Tieu, 2011). These factors together make rats
an important and accessible model within neuroscience research.
6-Hydroxydopamine Rat Model of Parkinson’s Disease
PD has become a focus in animal research to answer questions not readily understood in
current human studies, which could not be feasibly or ethically implemented in human patients
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(Chia et al., 2020; Dauer & Przedborski, 2003, pp. 894-895; Pereira & Aziz, 2006). Animal
modeling for PD began in earnest after Carlsson et al. (1957) discovered that haloperidol and
reserpine created an acute Parkinsonian phenotype in rodent and rabbit models. Subsequently,
many drugs and neurotoxins have been used to create PD phenotypes and neuropathology in rats
(Blum et al., 2001; Tieu et al., 2011; Ungerstedt, 1968).
A common neurotoxin used to induce PD in rats is 6-Hydroxydopamine (6-OHDA)
(Blum et al., 2001, p. 141; Chia et al., 2020). 6-OHDA has an added hydroxyl group making it
chemically similar to the catecholamines, noradrenaline, dopamine, and adrenalin (National
Center for Biotechnology Information, 2022). 6-OHDA was originally discovered to decrease
noradrenaline in the heart by Porter et al. (1965, 1963). In the same decade, Tranzer and Thoenen
(1968, 1973) demonstrated 6-OHDA could be used to cause select depletion of adrenergic
neuron terminals. Following the discovery of 6-OHDA’s functions, Ungerstedt (1968)
established its utility in producing nigrostriatal dopaminergic degeneration through direct
injection into the SN.
While there are many neurotoxins used to model PD in animals, 6-OHDA is more
frequently is used (Chia et al., 2020) because of its consistent reproduction of parkinsonian
phenotype and neuropathology and its selectivity to noradrenergic and dopaminergic neurons
(Tieu, 2011). Greater specificity is gained when desipramine, a noradrenergic reuptake blocker,
is systemically administered to the animal. Desipramine prevents 6-OHDA reuptake at
noradrenergic neuron terminals protecting noradrenergic neurons from going into apoptosis (Lin
et al., 2012; Linnoila et al., 1982). Therefore, 6-OHDA can be taken up into dopaminergic
neurons by the same transporter for DA reuptake and causes cell death specifically in DA
neurons (Deumens et al., 2001; Blum et al., 2001; Sauer & Ortel, 1994, p. 413; Tieu, 2011).
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In contrast, MPTP has been found to be less effective in rats, the animal model of interest
in this study (Giovanni et al., 1994). Paraquat, another environmental neurotoxin that is used for
PD models, has age-dependent toxicity, nigrostriatal dopaminergic cell death is not consistently
observed, and can cause possible pulmonary harm inducing motor deficits making it unsuitable
for the current model. Similarly, rotenone, is also an environmental toxin. However, rotenone has
not been reliable in producing PD in animal models both in phenotype and neuropathology
(Tieu, 2011). Tieu (2011) and Chia et al. (2020) provide further comparison between other
neurotoxins.
As mentioned, the striatum, specifically the DS, is involved in voluntary movement
through dopaminergic activation of D1R of the direct pathway, and D2R of the indirect pathway.
To model PD in animals, neurotoxins such as 6-OHDA work to decrease and eliminate DA by
destroying the nigrostriatal pathway, which mimics motor deficits and neuronal degeneration.
Multiple studies have been conducted to best understand the mechanisms of action of 6-OHDA
(Blum et al., 2001; Deumens et al., 2001; Dauer & Przedborski, 2003; Przedborski et al., 1995;
Sauer & Ortel, 1994).
While the mechanisms of DA neuron degeneration by 6-OHDA are not entirely
understood, these studies have helped to elucidate the function of 6-OHDA. Additional
understanding of how 6-OHDA is illustrated in Figure 2 below by Blum and colleagues (2001).
Blum et al. (2001) details three mechanisms by which 6-OHDA is thought to work. When
injected 6-OHDA is taken up retrograde, or backwards, at the neuron terminal because of its
chemical similarity to dopamine. Once in the striatum, the following mechanisms are thought to
occur: Mechanism (1) once inside the cell, auto-oxidation, or the interaction between 6-OHDA
and intra-cellular oxygen causes oxidation producing quinones and reactive oxygen species
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(ROS) such as peroxides, superoxide radicals, and hydroxyl radicals. These ROS are cytotoxic
causing cell damage and disruption leading to death. Mechanism (2) in normal functioning, the
enzyme monoamine oxidase (MAO), metabolizes excess dopamine. However, when 6-OHDA is
present within the cell, MAO will also break it down because of its similar composition to
dopamine. When metabolized, 6-OHDA turns into hydrogen peroxide an ROS, which similar to
mechanism one, causes lipid peroxidization – dissolving cellular and organelle membranes and
interfering with redox potential, both leading to cell death. Mechanism (3) 6-OHDA is also
known to inhibit complex 1, the method by which mitochondria create adenosine triphosphate
(ATP), energy for the cell to function. Without cellular energy, the cell dies. Further, interference
with mitochondrial respiration includes possible uncoupling of oxidative phosphorylation also
inhibiting ATP production. Finally, 6-OHDA can also cause similar oxidative stress as the first
and second mechanisms, which can break down the mitochondrial membrane (Auten & Davis,
2009; Blum et al., 2001; Graves et al., 2020).
Figure 2.
Proposed Mechanisms of Action of 6-OHDA Toxicity
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Note. The mechanisms of action of 6-OHDA neurotoxicity are not well understood. This model
proposes three principal ways that 6-OHDA can cause cell death. First, by intra- or extra-cellular
auto-oxidation from reactive oxygen species. Second, reuptake of 6-OHDA into the cell is
broken down into hydrogen peroxide (H2O2) by MOA, dissolving the membranes and organelles.
Third, H2O2 inhibits complex 1, the energy production process within the cell. Copied with
permission from Blum et al., 2001.
The striatum is chosen as the target injection site for multiple reasons. Firstly, the rat
striatum is a larger brain region than the SNc lending itself as an easier target to hit for
stereotactic injection. Second, when 6-OHDA is injected into the striatum, DA degeneration
(neuronal death starting in the nerve terminal at the striatum and progressing to the cell body at
the SNc) occurs over a period of 1-3 weeks, leading to ~50% nigrostriatal cell death, whereas
injections into the SNc or medial forebrain bundle cause rapid cell death within one day causing
a severe lesion of around 90% degeneration (Dauer & Przedborski, 2003, p. 895; Przedborski et
al., 1995, pp. 631-632, 644; Robinson et al., 1994, p. 2691; Sauer & Oertel, 1994, p.412; Tieu,
2011).
Unilateral injections using 6-OHDA are often a preferred method for inducing PD in rats
so the contralateral side can act as a control (Dauer & Przedborski, 2003, p. 895). However,
unilateral injections often require higher doses of 6-OHDA, which could create too strong of a
lesion and subsequent motor deficits possibly confounding behavior in the open field test (Sauer
& Oertel, 1994). Additionally, PD in clinical patients is bilateral and bilateral lesioning is more
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representative of real PD progression. Moreover, behavioral (learning) or neurobiological
(neurogenesis) compensatory mechanisms are less of a concern (Deumens et al., 2001, pp. 312314). Therefore, rats in this experiment were bilaterally lesioned to produce weaker and more
progressive degeneration representative of clinical PD.
Hypothesis and Goals
Based on previous research, we hypothesized that acute and chronic STN DBS would
produce more anxiety-like behavior in a rat model of PD compared to PD rats that were not
stimulated. Our first goal was to determine if STN DBS induces anxiety-like behavior in a PD rat
model that does not display motor deficits. The second goal was to determine if acute and
chronic STN DBS produce differences in anxiety-like behavior in the PD rat model.
Methods
Subjects
All behavior experiments were performed with wild type Sprague Dawley rats (Envigo,
Madison, WI), N=19. Both female (n=7) and male (n=12) rats were utilized and selected at
random. Groups were randomly generated by computer; chronic stimulation (n=6), acute
stimulation (n=6), and no stimulation (n=7). A total of 34 rats were operated on; however, eight
did not respond to stimulation, four rat’s headcaps detached, two could not be analyzed because
of cord detection issues (software would not detect the cord attachment), and one died during
surgery. Total attrition rate was 44%. The above subject information can be found in Appendix
A. All laboratory procedures were reviewed and approved by the Mayo Clinic Institutional
Animal Care and Use Committee (IACUC), approval number A00004425-19, and conformed to
guidelines published by the National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals (National Research Council, 2011). Prior to surgery, rats were group-housed

15
in acrylic cages (128 in2) with wire racks to hold feed and water. Rats had ad libitum access to
food and water. Each cage had solid floors with bedding to absorb waste, provide warmth and
enrichment. Additional cage enrichment was provided in the form of treats and plastic toys. At
each step of the experiment, the animals were kept under standard 12-hour light/dark cycle and
conditions (21°C, humidity 45%). Animals were acclimated for at least one week before use to
reduce stress. Before and throughout the experiment, each rat was routinely held to familiarize
the rat to the researcher reducing anxiety and discomfort during handling. All surgeries were
performed on rats weighing 250-280g. Post-operation, all rats were identified via cage card and
were also single housed to ensure proper recovery and reduce interference with the electrode. All
efforts were made to minimize both the number of rats used and any discomfort that may be
experienced. During transportation to and from the lab, the rats were kept in their home cages
and covered with an opaque cloth blanket to reduce light and noise. All animals were observed
by Mayo Clinic Department of Comparative Medicine (DCM) staff and researchers for any
complications before and after surgery utilizing the Rat Grimace Scale, observation of coat color,
rat weight, and porphyrin staining (Turner et al., 2019). Routine sanitation was conducted by
DCM personnel. Clean personal protective equipment, lab coat and gloves, was always worn and
surfaces used to handle rats were cleaned with Oxivir surface disinfectant (Diversey Inc., Fort
Mill, SC).
Two days prior and three days after surgery, each animal received analgesia via oral
Ibuprofen-infused water (15mg/kg) to minimize discomfort, improve recovery, and increase gut
motility. Additional analgesia, buprenorphine HCL (.1ml/250-300g), was subcutaneously
administered to each rat just before surgery and administered every 8-12 hours for 48 hours postoperation. A heating pad was used to maintain the subject’s body temperature to 37.0±0.5 °C
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throughout the duration of anesthesia. Animals were monitored once daily for five days
following surgery for signs of distress and infection at the surgical site. If signs of infection or
distress were observed, topical antibacterial ointment was applied to the surgical site, or a
veterinarian was consulted for the appropriate methods of treatment.
At the termination of the study or if a humane endpoint arose (i.e., headcap comes off or
inability to ambulate) subjects were euthanized. Each rodent intraperitoneally received a lethal
dose of Pentobarbital (100mg/kg). Depth of anesthesia was measured with eye blink and toe
pinch reflexes and respiration and heartbeat were monitored. Each rat’s peritoneum was then
opened, and the heart was revealed. The right atrium was clipped for blood to leave the body.
Immediately, rats were transcardially perfused through a 25-gauge needle with phosphate
buffered saline followed by cold 4% paraformaldehyde. To ensure death, decapitation was used
as an adjunctive method using a rodent guillotine. The brains were then extracted and placed into
4% paraformaldehyde overnight and then moved to 20% sucrose solution to preserve the brain.
Surgery
A stereotaxic frame (Model 1900, David Kopf Instruments, Tujunga, CA) was used for
implantation of a twisted bipolar Pt/Ir Teflon-insulated 0.127mm diameter stimulating electrode
(Plastics One, Roanoke, VA) in the STN and for infusion of 6-OHDA (Sigma-Aldrich, St. Louis,
MO) in the DS. All surgical instruments, electrodes, and skull screws were sterilized daily in an
autoclave and in hot bead sterilization (260 °C) if multiple surgeries were conducted. Anesthesia
was induced in rats with 4% isoflurane and lowered to 1-2% isoflurane for maintenance. The
depth of anesthesia was monitored using toe pinch and eye blink reflexes. Then, the rats were
placed in the stereotaxic apparatus and secured using ear bars. Eye lubricant was gently placed
onto the eyes of each rat to prevent damage to and drying of the ocular region. Once secured,
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buprenorphine was subcutaneously injected on the back of the neck. Following analgesia, an
intraperitoneal injection of 25mg/kg desipramine (Sigma-Aldrich, St. Louis, MO) was
administered to avoid cell death of noradrenergic neurons. Next, the surgical sites on rats’ head
were shaved and cleaned with alcohol wipes and povidone-iodine. A midline incision of
approximately 1.5-2 cm was made in the skin over the skull with a scalpel to reveal bregma and
lambda for stereotaxic coordination. Hydrogen peroxide, saline, and cotton swabs were used to
clean the skull surface.
Coordinates for each lesion and electrode location were measured according to The Rat
Brain in Stereotaxic Coordinates by Paxinos and Watson (2004). An electric drill was attached
to the stereotactic frame; the first craniotomy bilaterally targeted the DS, and the second cranial
window was created for the stimulating electrode. Next, four sterile skull screws (BASi, West
Lafayette, IN) were used to provide a strong fixation of the head cap. All cranial holes were 12mm.
Once all openings were created, the striatal lesions were conducted. Using a
microinjector mounted to the frame, 6-OHDA (5 µg/µL) was micropipetted via Hamilton
Microliter syringe (Hamilton Company, Reno, NV) and 2.5 µL per site was bilaterally injected in
the DS at 0.5 µL/min according to the following coordinates: AP: +1.2 mm from bregma, ML:
+/-2.7 mm, DV: −4.2 mm from dura. A five-minute waiting period elapsed prior to removal of
the needle after each injection to avoid reflux and allow tissue diffusion. Finally, bone wax was
placed into the lesion holes to seal them. Subsequently, the stimulating electrode was attached to
the stereotactic frame and unilaterally inserted into the STN at AP: -3.8 mm from bregma, ML:
+2.4 mm, and DV: −7.6 mm from dura. The electrode was fixed to the skull using Metabond
(Parkell, Edgewood, NY), a quick drying adhesive, forming the headcap. Additional adhesive
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was placed around the skull screws. Once dry, another layer of adhesive was applied to ensure a
strong seal and headcap. Sutures were used as needed to secure excess tissue not covered by the
headcap. Following the second layer drying, the ear bars and frame were removed, and
Isoflurane and oxygen were stopped. Post-surgery, animals were placed back into their home
cage, body heat was maintained by heating pad, and recovery was monitored until consciousness
was regained. All rats received the bilateral striatal lesion and unliteral STN DBS.
Stimulation Parameters
Stimulation parameters were based on previously determined bounds used in both human
and rodent STN DBS to replicate clinically relevant parameters while appropriate for rats
(Jakobs et al., 2019, p. 4; Kuncel & Grill, 2004, pp. 2436, 2439; Mottaghi et al., 2020; Volkmann
et al., 2006). Stimulation was provided by an external pulse generator, MINCS alongside
MincsWare software (Neural Engineering Laboratory and Department of Engineering, Mayo
Clinic, Rochester, MN) to define the stimulator settings. A continuous biphasic squared electric
current was applied at 130 Hz and 60µs pulse-width to the STN. Current intensity was
determined individually based on each rat’s active motor threshold. Once the rat showed
dyskinetic movements (licking, paw twitching, head, or body turn) the current intensity was set
to 20% below the active motor threshold (Huotarinen et al., 2019; Ruge et al., 2011a, p. 2109;
Ruge et al., 2011b, p. 1916; Xu et al., 2011, p. 295). This process was done to ensure clinically
relevant amplitude was given without inducing any motor deficits that could confound the open
field test.
Prior to all behavioral tests, all rats were tethered starting at 14 days post-op in their
home cages to allow habituation of all animals to the cord and reduce possible anxiogenic effect
from the cord swaying, pulling, or touching the rats’ head. All rats were transported and tethered
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in the same testing room as the open field. Rats were supervised during tethering to monitor for
tangles or other safety concerns. Tethering is done by screwing the stimulating cord to the
electrode attached to the headcap. Only the rats in the chronic stimulation group, received
stimulation for 2 hours daily for one week prior to behavioral tests. Animals in the acute group
were only stimulated during the open field test. Animals in the no stimulation group did not
receive stimulation before or during the open field test.
Open Field Test
The open field test has been used to measure anxiety in rats for decades by observing
patterns of locomotion and other exploratory behaviors such as rearing and grooming (Harro,
2018; Denenberg, 1969). The open field behavior paradigm followed recommendations put forth
by Walsh and Cummins (1976) and previous studies using the paradigm with rodents (Kraeuter
et al., 2019; Seibenhener & Wooten, 2015; Tatem et al., 2014). The open field arena consisted of
a box, 60x60x40 cm, made from opaque blue polyvinyl chloride (PVC) and metal and was
maintained in the same location, a quiet room with minimal outside noise. Appendix B shows the
open field arena used in the experiment. The open field was illuminated from above using LED
adhesive lights directly above and brightness was supplemented by LED ceiling lights.
Illumination was kept at a moderate level to prevent influences on ambulation or wall hugging,
thigomotaxis. Rats underwent the open field behavioral paradigm after 21 days from DA lesion
induction. Once transported to the room with the open field, the rats were kept in their home
cages for an hour to habituate to the room and normalize after the stress of transportation. Each
rat was moved from their home cage by hand to the open field where they were tethered and
placed into the center to avoid place preference, i.e., staying near the wall rats were originally
placed at. Tethers were connected to external pulse generators held in baskets on the outside of
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the open field. Once placed in the open field arena, the researcher would step away and monitor
the rat from a stationary camera placed above the arena to minimize any possible distractions or
stress from sudden movements. All rats were recorded for 10 minutes once placed in the open
field. Between each recording, all surfaces of the open field were wiped down with a surface
disinfectant and deodorizer and let to dry. Each rat had one trial in the open field paradigm and
was placed back into its home cage after completion. EthoVision XT™ (Noldus Information
Technologies©, Leesburg, VA, USA) was used to analyze each rat’s behavior including velocity,
total distance traveled, time spent in inner and outer zones. The software was also used to
develop heat maps and timelapse tracking of the rat’s path.
Measures
Locomotor activity patterns, or locomotion, is a measure that has been widely studied in
the open field and is often the principal variable of interest (Walsh & Cummins, 1976).
EthoVision was utilized to measure total distance (cm), velocity (cm/s), and time (seconds) spent
in inner and outer zones. Total distance traveled is often the most reported measures of
locomotion used to capture exploratory behavior (Bailey & Crawley, 2009; Díaz-Morán, 2014;
Walsh & Cummins, 1976). Velocity is akin to total distance traveled and can also be seen as
another measure of rodent activity within the open field, though it is a less utilized measure
locomotion. Total distance and velocity are variables used to evaluate the overall motor function
(Walsh & Cummins, 1976).
Time spent in inner zones, or the center of the open field, compared to time spent in the
outer zones, thigmotaxis near the walls, are variables used in tandem to examine arousal and
anxiety-like behavior. Time spent near the wall of the open field (i.e. time spent in the outer
zone) is representative of greater anxiety-like behavior (Bailey & Crawley, 2009; Seibenhener &
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Wooten, 2015). In EthoVision zones were created (zones 1-16) to measure changes in
locomotion from the center to the periphery. The center was 50% of the total area of the arena
creating an inner zone of 30X30 cm, listed as zones six, seven, ten, and eleven within the video
tracking software. The periphery comprised the rest of the outer zones (zones one through five,
eight, nine, and twelve through sixteen). Appendix G shows the arena and the respective zones
subdivisions in EthoVision.
Grooming and rearing were visually analyzed using ImageJ (Laboratory for Optical and
Computational Instrumentation, University of Wisconsin). Self-grooming is viewed as a
behavior associated with arousal and is negatively associated with freezing and thigmotaxis,
indicators of anxiety-like behavior (Díaz-Morán, 2014; Estanislau et al., 2019; Spruijt, 1992). In
the present study, self-grooming was operationally defined using Estanislau et al. (2009)
description of rostral grooming. Estanislau and researchers defined rostral grooming as a fixedaction pattern “involving friction movements with the forepaws directed to the nose, face, head
and ears” (p. 112588). Examples of rostral grooming only included the definition by Estanislau
and colleagues. An example of rostral grooming from the present experiment can be seen in
Appendix C. Nonexamples of self-grooming included any grooming to the body such as
scratching, licking, or biting. A nonexample of self-grooming via using the back paw to scratch
the body can be seen in Appendix D. Grooming was measured by duration (seconds) and began
once the rat stopped in place and started the sequence of rostral grooming.
In the open field test, rearing has been described as an exploratory behavior that is
negatively correlated with freezing and thigmotaxis indicating activity and arousal, opposite of
anxiety-like behavior (Díaz-Morán, 2014). Rearing was defined as two paws leaving the floor of
the open field test both while standing on hind legs and either supported (on the wall) or
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unsupported (away from walls). Rearing was measured by count (number) of instances. An
instance of rearing was counted once the rat had both front paws off the floor of the open field.
Successive counts were only included if both paws came back down to the floor of the open
field. An example of both supported and unsupported rearing can be seen in Appendix E.
Nonexamples of rearing include only one paw coming off the floor, the rat looking upward with
no paws leaving the floor, and changing walls in the open field while already rearing. A
nonexample of rearing can be seen in Appendix F. Any instances of grooming and rearing that
were unclear by the observer were clarified by group decision from the second and third authors.
Therefore, interrater agreement was not calculated.
Results
Data were analyzed using Statistical Package for the Social Sciences Version 20® (SPSS;
IBM®, New York). Data were split up into both the initial five minutes of the recording and the
total ten minutes to examine behavior over time. Data for the total ten minutes are presented in
Appendices H-M. Behavioral data can often be abnormally distributed; therefore, a one-sample
Kolmogorov-Smirnov test to determine non-normality. All significance values were above .05
indicating data were normally distributed. Distribution data of the initial five minutes are shown
in Table 1 below.
Table 1.
Descriptive Statistics and One-sample K-S Test for Measures in the First Five Minutes of the
Open Field Test
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Data were analyzed using Analysis of Variance (ANOVA) for normally distributed data
per previous studies recommendations (Bailey & Crawley, 2009; Tatem et al., 2014). As seen in
Table 2 below, a one-way ANOVA comparison for the first five minutes of the data did not yield
significant results for any measure.
Table 2.
Descriptive Statistics and One-way ANOVA Results for All Measures in the First Five Minutes of
the Open Field Test
Measure
Stimulation
F(2, 16)
Measure % timeChronic
in % time in Acute
Rearing
Grooming No Stimulation
Total
Average
Stimulation
Outer
Inner
Count
(seconds) Distance Velocity
M
SD
M
SD
MTraveled SD (cm/s)
Zone
Zone
Total
2693.98 844.83 2416.09 1098.44 2337.88
71.09
.27
(cm)
Distance
N
19
19
19
19
19
19
Traveled
95.67
4.34
23.00
8.79
2475.03
12.57
(cm) M
SD
2.35 11.112.35 15.6712.94 9.42 6.6030.86 860.78
Rearing
21.17
14.03 3.31
2.77
D
.62
.62
.55
.61
.33
.41
Count
Sig.
.843
.843
.928
.846
1.000
.997
Grooming
13.81
4.20
7.90
8.04
5.26
4.66
3.59
(seconds)

Sig.

Velocity
(cm/s)**

.70

13.36

3.69

11.33

4.57

12.95

1.33

.37

.77

.09
.05
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Time Spent
in Outer
Zone
(seconds)

286.03

6.10

282.92

6.67

289.00

7.35

1.31

.30

Time Spent
in Inner
Zone
(seconds)

12.44

7.0

16.01

6.83

10.78

7.4

.93

.10

Percentage
95.84
2.32
94.63
2.27
96.41
2.46
.94
.41
of Time in
Outer Zone
Percentage
4.16
2.32
5.37
2.27
3.59
2.46
.94
.41
of Time in
Inner Zone
Note. **Velocity was found to be in violation of Levene’s test for equality of variances, F(2,
16)=3.85, p=.043. Therefore, a Welch’s test was conducted and presented above; adjusted
degrees of freedom F(2, 7.47).
Figure 3 below shows the time spent in the inner and outer zones for the first five minutes
of the open field test. Animals that did not receive STN DBS spent most of the time in the outer
zone, 96%, and STN DBS delivered acutely or chronically did not change this pattern of
behavior, 95% and 96% respectively. As expected, the percentage of time spent in the inner zone
matches the percentage of time spent in the outer zone. Table 2 above shows the descriptive
statistics of the one-way ANOVA.
Figure 3.
Outer and Inner Zones for First Five Minutes in the Open Field Test
A)

25

B)

Note. Average of percentage of time in seconds spent in the outer zone (A) and inner zone (B) of
the open field arena. No STN DBS (n=7), Acute STN DBS (n=6), and Chronic STN DBS (n=6).
Data are represented as mean ± SEM, one-way ANOVA.
Figure 4 below shows the time spent grooming in the first five minutes of the open field
test. Animals that did not receive STN DBS spent less time grooming, 5s, than STN DBS
delivered acutely or chronically, 8s and 14s respectively. While rats that did not receive STN
DBS groomed less, Table 2 above, shows no significant difference between groups and presents
descriptive statistics of the one-way ANOVA.

Grooming

Figure 4.

16
Grooming in the First Five Minutes of the Open Field Test
14

Seconds

12
10
8
6
4
2
0

No STN DBS

Acute STN DBS

Chronic STN DBS
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Note. Average time in seconds spent grooming in the open field arena. No STN DBS (n=7),
Acute STN DBS (n=6), and Chronic STN DBS (n=6). Data are represented as mean ± SEM,
one-way ANOVA.
Figure 5 below shows the number of times reared over the first five minutes of the open
field test. Animals that did not receive STN DBS reared more, 31 instances, than STN DBS
delivered acutely or chronically, 16 instances and 21 instances respectively. While rats that did
not receive STN DBS reared more, Table 2 above, shows no significant difference between
groups and presents descriptive statistics of the one-way ANOVA.
Figure 5.
Rearing in the First Five Minutes of the Open Field Test
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35
30

Count

25
20
15
10
5
0

No STN DBS

Acute STN DBS

Chronic STN DBS
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Note. Average number of rearing instances in the open field arena. No STN DBS (n=7), Acute
STN DBS (n=6), and Chronic STN DBS (n=6). Data are represented as mean ± SEM, one-way
ANOVA.
Figure 6 below shows the total distance traveled (cm) and velocity (cm/s) over the first
five minutes of the open field test. Animals that did not receive STN DBS had less total distance
traveled, 2338cm, than STN DBS delivered acutely or chronically, 2416cm and 2694cm
respectively. Animals that did not receive STN DBS had similar velocity, 13cm/s, as STN DBS
delivered acutely or chronically, 11cm/s and 13cm/s respectively. While rats that did not receive
STN DBS traveled less distance and had similar velocity, Table 2 above, shows no significant
differences between groups and presents descriptive statistics of the one-way ANOVA.

Figure 6.
Total Distance Traveled in the First Five Minutes of the Open Field Test
A)
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Note. Average total distance traveled in centimeters (A) and average velocity in centimeters per
second (B) in the open field arena. No STN DBS (n=7), Acute STN DBS (n=6), and Chronic
STN DBS (n=6). Data are represented as mean ± SEM, one-way ANOVA.

Discussion
In this study we demonstrate that acute and chronic STN DBS does not produce more
anxiety-like behavior in a rat model of PD compared to rats that were not stimulated. Goal one
was not found, as STN DBS does not increase anxiety-like behavior in a parkinsonian rat model
that does not display motor deficits. Goal two was also not verified, as acute and chronic STN
DBS was not found to be significantly different on any measure.
We initially hypothesized that STN DBS would induce anxiety-like behavior in the 6OHDA PD rat model. This hypothesis was formulated based on clinical reports of transient
anxiety symptoms or long-term side effects by parkinsonian patients undergoing STN DBS.
Additionally, Reymann et al. (2013) found that excitotoxic lesion of the STN using ibotenic acid
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induced anxiety-like behavior in rats in the elevated plus maze. However, our findings are
contrary to our hypothesis and to these previous studies. A possible explanation for our diverging
results is the placement of the electrode in the STN and how the electric field created by the
stimulation differently affects the STN itself and surrounding fibers of passage. For example,
Abulseoud et al. (2016) investigated fifteen individuals with severe PD who underwent bilateral
STN DBS in the medial and lateral STN. During parameter setting, seven patients reported
twelve acute episodes of anxiety (feeling apprehensive and uncertain), especially with higher
voltage. In rats the electrode is quite large compared to their STN; therefore, we stimulate the
entire STN leaving us unable to selectively target the dorsal or ventral areas of the STN.
Anderson et al. (2005) conducted a comparison of GPi DBS vs. STN DBS on motor
deficits and non-motor symptoms. They examined 20 patients diagnosed with PD who had STN
DBS (n=10) and GPi DBS (n=10). Though the focus was on postoperative outcomes, two STN
DBS patients experienced acute anxiety (feeling nervous, tense, and restless) during parameter
setting. No patients in the GPi DBS group reported feelings of anxiety. They suggested that
anxiety during DBS parameter setting is common, indicating acute stimulation as a possible
factor in patient reports of anxiety, though our results did not find a significant difference among
acutely stimulated rats.
Another study by Houeto et al. (2002) retrospectively investigated twenty-four
individuals with bilateral STN DBS. At 6-months post operation the researchers conducted
behavioral assessments. Of the twenty-four participants, eighteen reported generalized anxiety
after surgery; ten of them reporting anxiety without any specific focus, and three who’s anxiety
could not be described. Houeto and colleagues stated that medication (Levodopa) and STN
stimulation are likely contributors to anxiety. It is unclear why our study did not find results in
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the chronically stimulated STN DBS group that parallel those in Houeto and researcher’s study;
however, answers may be found in their stimulation parameters or in the administration of
Levodopa.
Notwithstanding the evidence described above, other clinical studies reported that anxiety
symptoms did not surge with STN DBS. Rothlind et al. (2007) examined neuropsychological
performance following unilateral STN DBS (n=19) and unilateral compared to bilateral STN
DBS (n=14) using the Speilberger State-Trait Anxiety Inventory. Rothlind and colleagues noted
that all participants were on Levodopa. Neuropsychological testing was completed on average 13
days pre-op and an average of 6-months post-op of the first unilateral STN DBS surgery. No
significant difference in state- or trait-anxiety scores were found for unilateral STN DBS.
Patients then received another surgery an average of 7-months after the first to implant a second
stimulating electrode contralaterally, and the final neuropsychological assessment was given an
average of 15 months post-operation. Again, no significant differences were found before and
after unilateral and bilateral STN DBS. These findings parallel our chronic STN DBS group,
which was not significantly different on measures of anxiety-like behavior. A similar study by
Lopiano et al. (2001) bilaterally implanted STN DBS in 16 patients. Participants received the
State-Trait Anxiety Inventory and were tested before surgery and 3-months after. No significant
differences were found from pre- to post-operation on the State-Trait Anxiety Inventory.
Examining the first three studies, it is possible that bilateral STN DBS, higher voltage,
and medication or a combination may all play a role in eliciting anxiety. However, the results
provided by Rothlind et al. (2007) and Lopiano et al. (2001) conflict with these findings; both
unliteral and bilateral STN DBS, Levodopa, and high amplitude stimulation were involved.
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Future studies should look to examine bilateral STN DBS, varying voltage strengths, and
Levodopa to examine their independent and combined effects on anxiety.
Our results may differ from previous literature for another key reason. One of the
principal limitations of the present study is the lack of histological analysis. Histological analysis
is a necessary component of assessing and validating procedures conducted with animal models
such as neurochemical lesions and electrode implantation (Knoblaugh et al., 2018). Without
tissue examination, we cannot determine if the electrode was placed correctly into the STN nor if
the 6-OHDA lesion hit the striatum and to what extent nigrostriatal degeneration occurred.
Moreover, this type of analysis is important as previous reviews have noted that variation
between lesions in each subject (Amalric et al., 1995; Deumens et al., 2002; Sauer & Oertel,
1994, pp. 403-404). Currently, histological analysis is pending and will help us understand if
surgical errors played a role in non-significant results. Though we do not have tissue results, the
second part of goal one was met. Our model did not have observable motor deficits. The total
ten-minute analysis of the open field test was used to examine motor function and habituation,
rats often will display less anxiety-like behavior over time and repeated testing. Thus, the first
five minutes then can prove the most useful in examining differences in behavior (Badstuebner et
al., 2017; Creed et al., 2013, pp. 508-509). Appendix M demonstrates similar total distance
traveled and velocity for all groups over ten minutes in the open field arena.
Another limiting factor was the total sample size. Investigating differences between small
group sizes diminishes the power of the study and allows more error to be introduced hurting the
possibility of significant results unless the process under examination produces strong responses.
However, as noted above, anxiety as a non-motor symptom of STN DBS has been reported as
both acute and chronic, and as improving, no change, or becoming worse postoperatively. Future
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studies should work to increase the number of animals included in examination of anxiety as a
non-motor symptom of STN DBS.
An additional reason why we did not find differences between groups is from a possible
ceiling effect of the open field. Rats have a preference to avoid open spaces and display
thigmotaxis naturally as an anxiety-like behavior in response to stress (Ennaceur & Chazot,
2016; Seibenhener & Wooten, 2015). Therefore, while still an important measure, rats already
display high levels of thigmotaxis, which means experimental interventions may need a strong
effect to produce significant differences. Several studies have reported possible ceiling effects
when using rodents in the open field test and other behavioral tests of anxiety such as the
Elevated Plus Maze (Brenes et al., 2009; Shoji et al., 2021; Thompson et al., 2015).
The open field has also been criticized for being used as a test for anxiety (Harro, 2018;
Walsh & Cummins, 1976). Harro (2018) and Walsh and Cummins (1976) have both reported on
the unvalidated and unreliable measures used when employing the open field paradigm. Both
studies argue that many factors can influence anxiety-like behavior (illumination, noise, smell,
handling) to being placed in a novel environment can elicit anxiety. Additionally, Harro states
that thigmotaxis is an unreliable measure because rats have a general tendency to prefer enclosed
and protected spaces. These criticisms are all valid. For instance, Appendices B-E reveal another
possible limitation in the present study. Depending upon the angle of the camera and brightness
of lights in the room with the open field, some shadows creating darker areas, preferential areas
for rats, may influence rats to spend more time in those areas. Hence, why current research aims
to validate behavioral measures of anxiety-like behavior and implement standard procedures
such as those followed in the current experiment.
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While there are drawbacks to the open field test, Tatem et al. (2014) provide a succinct
argument for its current use writing:
a) it is a comprehensive assessment of both locomotor and behavioral activity, which is
strongly, but not always correlated with locomotive function; b) it is an easy measure to
perform; c) it requires no animal handling during testing; d) it is a noninvasive measure
that can be performed more than once throughout the duration of a study; e) no special
training is needed to perform the test; f) multiple animals can be tested at one time; and
g) it is a clinically relevant outcome measure. (p. 6)
Further limitations can be found looking at the setup of the open field. First, the
placement of the camera above the open field made it difficult to adequately view the rats’ paws
and subtle movement. As a result, verifying if both paws left the floor to count an instance of
rearing was uncertain if the rat was facing with its back toward the camera. Similarly, counting
how long or if a rat was engaged in grooming could be difficult for the same reason.
Interobserver agreement could have helped reduce this problem by providing measure
verification. Future research using open field should include interobserver agreement to increase
measure reliable when completing measures by hand. Moreover, interested researchers should
consider placing an additional camera closer to the open field to best capture rearing and
grooming.
Another obstacle that arose during the experiment was the highly saturated color of the
open field arena and reflection from the plastic (see Appendix B). Prior to video analysis in
EthoVision, each video was changed to black and white to reduce difficulties during software
detection. However, the contrast between the black and white open field and the silver tether
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created software interference. Future analysis should consider using a matte-colored material for
the open field and/or a color that is different than that of their subject and tether.
Thinking about the measures of the open field, a prior study using the open field with
mice reported that unsupported rearing is similar to measures such as time spent in the center and
is reduced during stress, whereas supported rearing is indicative of locomotion such as distance
traveled measures (Sturman et al., 2018). While this may not translate to rats, it is worth
considering counting both rearing types separately for a better understanding of anxiety-like
behavior during data analysis.
Due to the present drawbacks of the open field test, researchers should contemplate
additional behavioral tests of anxiety-like behavior in rodents. Bouwknecht & Paylor (2008)
write about behavioral tests saying, “determining anxiety in rodents is more complicated than
measuring a single parameter in a particular paradigm. It is important to use proper controls such
as additional measures in the same or other procedures, as well as a conservative estimation of
the chance of finding an actual effect” (p. 385). Another popular and validated test is the elevated
plus maze (EPM), a cross-shaped maze elevated off the ground that has two enclosed arms and
two open arms. Similar to the open field test, the EPM examines entries into the open versus
enclosed spaces as measures of anxiety-like behavior, time spent in the enclosed arms indicative
of more anxiety-like behavior. In the EPM, factors such as illumination and the rodent being
placed into the maze did not appear to affect behavior. The EPM is also less correlated with other
locomotor and exploratory measures. (Pellow et al., 1985). Rosso et al. (2021) conducted a metaanalysis on the effects of anxiolytics and the reliability of behavioral tests for mice. Reviewing
17 behavior paradigms, Rosso and colleagues concluded that the EPM’s time spent in the
enclosed and open arms along with the light-dark box’s (LDB) time spent in the light
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compartment were the two paradigms able to detect effects of anxiolytic drugs and detect the
reliably with significant effect sizes. This review may explain the difficulty that the open field
test has in detecting anxiety-like behavior in the presented results.
Overall, we can conclude acute and chronic STN DBS does not produce more anxietylike behavior. Given the above limitations, future experiments investigating anxiety-like
behavior in rodent models of PD using DBS should take the following factors into account: (1)
Optimization of STN DBS parameters, (2) Adding a positive drug control such as caffeine to
examine anxiogenic effects to demonstrate whether untreated animals are displaying exacerbated
anxiety-like behavior, (3) Similarly, adding a negative drug control such as benzodiazepines to
examine anxiolytic effects to demonstrate that the PD model is responsive to the behavior
paradigms, and (4) Conducting an additional behavioral test such as the EPM or LDB to confirm
anxiety-like behavior.
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Appendix A
Rat Information Including Number, Sex, Group, Exclusion, and Attrition
Rat Number
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37

Sex
m
m
m
m
m
m
m
m
m
m
f
f
m
m
f
f
m
m
m
m
f
f
f
f
f
m
m
m
f
f
f
m
m
m

Group/Reason
Not Included
Chronic
Acute
Chronic
NR
Acute
SE
No Stim
No Stim
NR
Chronic
NR
Chronic
Acute
Acute
Chronic
No Stim
HD
CDI
NR
NR
No Stim
HD
NR
CDI
No Stim
Acute
Chronic
No Stim
NR
Acute
No stim
NR
HD
HD

Attrition
NR= 8
SE= 1
CDI= 2
HD= 4
Total Attrition= 15
Total %= 44
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Note. NR= Non-responder, did not respond to stimulation; HD= Headcap detached and was
euthanized; SE= Surgical error, died during surgery; CDI= Cord detection issues, could not be
stimulated.
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Appendix B
Open Field Arena Utilized in the Present Experiment

15 cm
Appendix B

30 x 30cm

60x60x40 cm
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Appendix C
An Example of the Grooming Sequence

1)

2)

3)

4)

Note. Seen in image 1 the rat has stopped, moving image 2 the rat has begun to lick and
clean its paws. In images three and four, the rat has raised its left and right paw over its head and
across the ears back to the mouth.
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Appendix D
Nonexamples of Grooming Behavior

Note. Nonexample of the rat using its hind paw to scratch its body.
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Appendix E
Examples of Supported and Unsupported Rearing

Note. The photo on the left illustrates supported rearing with both paws on the wall. The photo
on the right shows unsupported rearing.
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Appendix F
Nonexample of Rearing Behavior

Note. The rat has one paw on the floor and one on the wall, which is considered a nonexample
of rearing.
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Appendix G
Zone Setup in EthoVision for Center and Border Measures

62

Measure % time in
Outer
Zone
N
M
SD
D
Sig.

19
96.71
1.99
.92
.361

% time in
Inner
Zone
19
3.29
1.99
.92
.361

Rearing
Count

19
41.80
22.01
.69
.723

Grooming
(seconds)

19
24.50
15.66
.44
.991

Total
Distance
Traveled
(cm)
19
4456.91
1614.21
.45
.987

Velocity
(cm/s)

19
12.09
3.01
.41
.996

Appendix H
Descriptive Statistics and One-sample K-S Test for Measures for Total Ten Minutes of the Open
Field Test
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Appendix I
Descriptive Statistics and One-way ANOVA Results for All Measures in the Total Ten Minutes of
the Open Field Test
Measure
Total
Distance
Traveled
(cm)
Rearing
Count
Grooming
(seconds)

Chronic
Stimulation
M
SD
4914.71 1567.04

Acute Stimulation

No Stimulation

F(2, 16)

Sig.

M
4483.80

SD
2067.28

M
4041.46

SD
1340.7
5

.45

.65

44.50

17.20

27.50

18.49

51.71

24.40

.13

.23

31.03

15.65

23.35

18.61

19.88

13.21

.83

.46

Velocity
(cm/s)

12.49

3.55

11.50

4.12

12.26

1.39

.16

.85

Time Spent
in Outer
Zone
(seconds)

573.27

10.90

571.04

19.31

579.21

14.63

.50

.62

64
Time Spent
in Inner
Zone
(seconds)

20.09

11.17

20.42

12.87

18.40

13.62

.05

.95

Percentage
of Time in
Outer Zone
Percentage
of Time in
Inner Zone

96.62

1.85

96.56

2.13

96.92

2.27

.06

.95

3.38

1.85

3.44

2.13

3.08

2.27

.06

.95

Appendix J
Outer and Inner Zones for Total Ten Minutes in the Open Field Test
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Percentage of Time (s)

Outer Zone
100
90
80
70
60
50
40
30
20
10
0

No STN DBS

Acute STN DBS

Chronic STN DBS

Percentage of Time (s)

Inner Zone
100
90
80
70
60
50
40
30
20
10
0

No STN DBS

Acute STN DBS

Chronic STN DBS
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Note. Average of percentage of time in seconds spent in the outer zone (A) and inner zone (B) of
the open field arena. No STN DBS (n=7), Acute STN DBS (n=6), and Chronic STN DBS (n=6).
Data are represented as mean ± SEM, One-way ANOVA.

Appendix K
Grooming in the Total Ten Minutes of the Open Field Test

Grooming
35
30
Seconds

25
20
15
10
5
0

No STN DBS

Acute STN DBS

Chronic STN DBS

Note. Average time in seconds spent grooming in the open field arena. No STN DBS (n=7),
Acute STN DBS (n=6), and Chronic STN DBS (n=6). Data are represented as mean ± SEM,
one-way ANOVA.
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Appendix L
Rearing in the Total Ten Minutes of the Open Field Test

Rearing
60
50

Count

40
30
20
10
0

No STN DBS

Acute STN DBS

Chronic STN DBS

Note. Average number of rearing instances in the open field arena. No STN DBS (n=7), Acute
STN DBS (n=6), and Chronic STN DBS (n=6). Data are represented as mean ± SEM, one-way
ANOVA.
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Appendix M
Total Distance Traveled in the First Five Minutes of the Open Field Test
A)

B)

69

Note. Average total distance traveled in centimeters (A) and average velocity in centimeters per
second (B) in the open field arena. No STN DBS (n=7), Acute STN DBS (n=6), and Chronic
STN DBS (n=6). Data are represented as mean ± SEM, one-way ANOVA.

